AUSTIN, Texas, Nov. 4, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has been invited to present at the Lazard Capital Markets 8th Annual Healthcare Conference. The conference will be held at The Pierre Hotel in New York City on November 15-16, 2011. Vermillion's president and CEO, Gail Page, is scheduled to present on Tuesday, November 15, 2011 at 8:00 a.m. Eastern time, with one-on-one meetings held in the morning. Management will discuss the company's business plan and objectives for the remainder of 2011. The presentation will be available via webcast at http://wsw.com/webcast/lz11/vrml/. A replay link will also be available for 90 days following the live presentation on the company's website at www.vermillion.com. Vermillion continues to see increasing adoption of OVA1® and recently received a notice of allowance for its fifth patent covering a combination of biomarkers associated with Peripheral Artery Disease. For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your Lazard Capital Markets representative. About Lazard Capital Markets Lazard Capital Markets LLC provides corporate finance advisory services. It offers mergers and acquisitions, restructuring, and capital raising advisory services. The firm provides equity and fixed income sales and trading services. Additionally, it offers corporate underwriting services. The company was founded in 2005 and is based in New York, New York. For more information, please visit www.lazardcap.com. About Vermillion Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com. SOURCE Vermillion, Inc.